top glp-1 drugs for type 2 diabetes 2025 trends 2025: real-world data, patient outcomes & future therapies New GLP-1 Guidelines for Type

This body of evidence provides a mechanistic rationale for advancing GLP-1R agonists as candidate pharmacotherapies for AUD, with relevance for individuals characterized by specific genetic profiles, nicotine co-use, or metabolic vulnerability

The product is labeled strictly for Research Use Only (RUO), meaning it is intended exclusively for laboratory, investigational, and scientific research purposes

Although early pharmacovigilance reports suggested a possible association with suicidality, larger subsequent studies have not demonstrated a causal link, though ongoing monitoring remains advisable

Steven Kliewer, University of Texas Southwestern, and were provided by Dr